New name, but same old problems for Posimir as FDA hits Durect again

Ben Adams

may have changed the of its post-pain gall bladder surgery drug from "Posidur" to "" this year, but this has not stopped its run of back luck as the FDA has told the Cupertino, CA-based biotech that it must make a number of amendments to its Phase III Persist trial for the treatment.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS